Brendan Frett

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 9

Top Venues

RSC medicinal chemistry

Journal of medicinal chemistry

ChemMedChem

Chemical communications (Cambridge, England)

University of Arkansas for Medical Sciences

University of Arizona (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Arkansas for Medical Sciences

United States

Assistant Professor :: Pharmaceutical Sciences

Education History

University of Arizona

United States

PHD :: Pharmaceutical Sciences

Publications

Mason McCrury, Kennith Swafford, Sydnye L Shuttleworth, Syed Hassan Mehdi, Baku Acharya, Debasmita Saha, Kevin Naceanceno, Stephanie D Byrum, Aaron J Storey, Ying-Zhi Xu, Claire Doshier, Vijay Patel, Ginell R Post, Annick De Loose, Analiz Rodriguez, Leonard D Shultz, Fenghuang Zhan, Donghoon Yoon, Brendan Frett, Samantha Kendrick
Bifunctional inhibitor reveals NEK2 as a therapeutic target and regulator of oncogenic pathways in lymphoma. Molecular cancer therapeutics (2023)
Baku Acharya, Debasmita Saha, Daniel Armstrong, Baha'a Jabali, Maha Hanafi, Alan Herrera-Rueda, Naga Rajiv Lakkaniga, Brendan Frett
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules. RSC medicinal chemistry 15 (2) (2023)
Baku Acharya, Debasmita Saha, Daniel Armstrong, Baha'a Jabali, Maha Hanafi, Alan Herrera-Rueda, Naga Rajiv Lakkaniga, Brendan Frett
Kinase inhibitor macrocycles: a perspective on limiting conformational flexibility when targeting the kinome with small molecules. RSC medicinal chemistry 15 (2) (2023)
Lingtian Zhang, Marialuisa Moccia, David C Briggs, Jaideep B Bharate, Naga Rajiv Lakkaniga, Phillip Knowles, Wei Yan, Phuc Tran, Anupreet Kharbanda, Xiuqi Wang, Yuet-Kin Leung, Brendan Frett, Massimo Santoro, Neil Q McDonald, Francesca Carlomagno, Hong-Yu Li
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose. Journal of medicinal chemistry 65 (2) (2022)
Baku Acharya, Debasmita Saha, Daniel Armstrong, Naga Rajiv Lakkaniga, Brendan Frett
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. RSC medicinal chemistry 13 (7) (2022)
Baku Acharya, Sayem Miah, Brendan Frett
Targeting TGF-β: triumphs and challenges. Future medicinal chemistry 14 (7) (2022)
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Baku Acharya, Noemi Garcia Garcia, Erica Lane Smith, Brendan Frett
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. Journal of medicinal chemistry 64 (16) (2021)
Debasmita Saha, Katie Rose Ryan, Naga Rajiv Lakkaniga, Erica Lane Smith, Brendan Frett
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach. ChemMedChem 16 (10) (2021)
Jie Lei, Gui-Ting Song, Liu-Jun He, Ya-Fei Luo, Dian-Yong Tang, Hui-Kuan Lin, Brendan Frett, Hong-Yu Li, Zhong-Zhu Chen, Zhi-Gang Xu
One-pot construction of functionalized aziridines and maleimides via a novel pseudo-Knoevenagel cascade reaction. Chemical communications (Cambridge, England) 56 (14) (2020)

Brendan Frett.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Brendan Frett